The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events (heart attack, stroke, and cardiovascular death) by 20% in adults with overweight or obesity and established heart disease (Lincoff et al., SELECT trial, New England Journal of Medicine , 2023)
Market growth is further supported by urbanization, the expansion of endocrinology and specialty clinics, and broader access to healthcare services
This reduces the concentrated volume at each site and may decrease reaction severity
CagriSema , combining semaglutide with cagrilintide (an amylin analog), represents another approach
This triple action counteracts the signs of aging, delivering noticeable natural results after just one treatment
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease (TRIUMPH-3)